Navigation Links
Ophthonix Completes Series AA Financing at $25.9 Million
Date:5/26/2009

Funding supports the continued U.S. roll-out of the Z-View(R) Aberrometer and wavefront guided iZon(R) High Resolution Lenses

VISTA, Calif., May 26 /PRNewswire/ -- Ophthonix, a company that has developed advanced vision-correction products that provide consumers with superior optical clarity and crispness of vision, just announced that it has closed its $25.9 million "Series AA" financing. In addition to a significant investment by a new private investor, each of the company's current top-tier investors participated in the "Series AA" funding: Kleiner Perkins Caufield & Byers, Enterprise Partners, DAG Ventures, Gund Investment Corporation, InterWest Partners, Trex Enterprises and Wasatch Advisors' Cross Creek Capital Fund. The "Series AA" financing enables Ophthonix to continue the roll-out of the Z-View(R) Aberrometer and iZon(R) High-Resolution Lens throughout the U.S.

"We are very excited by our success in securing the support of a new private investor and the ongoing commitment of our world-class investment partners. The large investment by the new investor validates our business proposition and the company's valuation," said Stephen Osbaldeston, Ophthonix CEO. "First quarter 2009 sales growth in excess of 30 percent and our continued increase in prescribing optometrists underscores the significance of our technology. With this investment round we are well-positioned to continue to build distribution of our high-definition vision iZon Lenses among leading optometrists, while capitalizing on our recent strides in improving manufacturing margins and reducing operating expenses," Osbaldeston continued.

The iZon Lens design is based on a patient's optical fingerprint, or iPrint(TM) as measured by the company's Z-View Aberrometer. As a result, the iZon Lens can address the symptoms associated with the unique imperfections, or aberrations, of the eye that can cause sub-optimized visual clarity if not corrected.

"Patients tell us that the iZon Lens gives them a quality of vision that they have never before experienced -- sharpness of images, richer colors, better depth perception, reduced glare and enhanced night vision," noted Osbaldeston. "Recent clinical studies conducted by the University of Illinois at Chicago have validated that the iZon ML(TM) Lens delivered significant advantages across a range of visually challenging conditions, including glare, low contrast, reading signs at a distance and low light."

One of Ophthonix's earliest investors mirrored the enthusiasm of Osbaldeston. "From our initial introduction to the company's proposed optical system, we saw the breakthrough potential of a disruptive technology that could detect, measure and correct the visual symptoms that have limited the quality of vision experienced by the hundreds of millions of people around the world who suffer from high order aberrations," said Drew Senyei, M.D., and managing director of Enterprise Partners. "Our firm has been very excited to see such significant growth in distribution and lens sales, even in these challenging economic times."

One of the practitioners using the company's products, Dr. Mario Gutierrez of San Antonio, Texas, noted, "We have the Z-View Aberrometer in our practice, Alamo Heights Vision Source. Our practice fits the iZon Lenses on more than 25 patients per month, and they are benefiting from the crisp, clear vision these lenses provide. My patients love the iZon Lenses and so does my banker."

About Ophthonix

Ophthonix, Inc., a San Diego-based vision correction company, is changing forever the way people see the world. Customized iZon(R) High Resolution Lenses allow wearers to see the world in high definition--clearer, sharper and more vividly than ever before. The proprietary and patented process is the first-ever vision correction technology that addresses the problems associated with the unique variations in each person's eyes, allowing for customized eyeglass lenses. For more information, visit www.izonlens.com or contact media@ophthonix.com, (760) 842-5600.

About Enterprise Partners

Enterprise Partners is a venture capital firm investing in privately held early stage and emerging companies with particular strengths in information technology, communications, life sciences and selected consumer products and services. One of the top-performing venture capital firms in the United States with over a $1 billion of capital under active management, Enterprise Partners is headquartered in La Jolla, CA, phone (858) 731-0300, website: www.epvc.com.

About DAG Ventures

Doug Ackerman & Goodrich (DAG) Ventures is a leading diversified capital firm with a portfolio of companies in life sciences, information technologies and energy technologies, including Plaxo, Blue Lane, Matrix Memory and Podshow. DAG Ventures is located at 251 Lytton Ave., Ste. 200, Palo Alto, CA 94301, phone: (415) 788-2755, website: www.dagventures.com.

About Kleiner Perkins Caufield & Byers

Kleiner Perkins Caufield & Byers is a leading venture capital partnership headquartered in Menlo Park, CA. The firm has backed many industry-leading companies including AOL, Google, Compaq, Genentech, Hybritech, and Netscape. Kleiner Perkins Caufield & Byers is located at 2750 Sand Hill Road, Menlo Park, CA 94025, phone: (650)233.2750, website: www.kpcb.com.

About Gund Investment Corporation

Gund Investment Corporation is the private investment firm of Gordon Gund. The firm invests in privately held companies as well as public securities and real estate. A prominent philanthropist, Mr. Gund is co-founder of The Foundation Fighting Blindness, a non for profit organization driving research to find causes, treatments and cures for retinitis pigmentosa, macular degeneration, Usher Syndrome, and other retinal degenerative diseases. Gund Investment Corporation is located at 14 Nassau Street, Princeton, NJ 08542, phone (609) 921-3633.

About InterWest Partners

InterWest Partners (www.interwest.com), founded in 1979, is a leading diversified venture capital firm focused on building long-term relationships with entrepreneurs and portfolio companies. With more than $2 billion of capital raised, including its new investment fund of $600 million, InterWest has 11 experienced partners in Menlo Park, CA and Dallas, TX, who bring together deep domain knowledge in life sciences and information technology.

About Trex Enterprises

Established in 1978, Trex Enterprises is a privately owned, high-tech company specializing in government and commercial R&D in the field of applied physics, as well as supporting the launch of new ventures. Among its other ventures are Cross-Fiber, Inc., Lorea Corporation and e-Phocus, Inc. Trex Enterprises is located at 10455 Pacific Center Court, San Diego, CA 92121, phone: (858) 646-5300, website: www.trexenterprises.com.

About Wasatch Advisors

Wasatch Advisors, investment adviser to institutional clients and a family of mutual funds, has specialized in small cap growth investing since 1975. Wasatch Advisors is located at 150 Social Hall Avenue, 4th Floor, Salt Lake City, UT 84111, phone (801) 533-0777, website: www.wasatchadvisors.com.


'/>"/>
SOURCE Ophthonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: